Mink Therapeutics Inc (INKT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $47.95M
Last updated: Nov 17, 2026 at 4:15 PM ET
Mink Therapeutics Inc (INKT) Statistics
Mink Therapeutics (INKT) has a market cap of $47.95M and an enterprise value of $40.48M. It kept -5512.48% of revenue as net income over the last 12 months. Revenue fell 99.99% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 15.58% below the market cap, as cash exceeds debt.
| Market Cap | $47.95M |
|---|---|
| Enterprise Value | $40.48M |
| Latest price (Nov 17, 2026) | $9.29 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 11, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 27.18% over 52 weeks and trades 15.62% below its 50-day average.
| Beta (1Y) | 0.61 |
|---|---|
| 52-Week Change | -27.18% |
| 1-Month Change | -2.88% |
| 3-Month Change | -16.58% |
| 6-Month Change | -10.29% |
| 5-Year Change | -94.11% |
| Total Return (1Y) | -27.18% |
| Total Return (3Y CAGR) | -3.40% |
| Total Return (5Y CAGR) | -43.43% |
| Return vs SPY (1Y) | -29.46% |
| Max Drawdown (1Y) | -36.64% |
| Max Drawdown (3Y) | -86.66% |
| Sharpe Ratio (1Y) | -0.28 |
| Correlation with SPY (1Y) | 0.12 |
| 50-Day Average | $11.01 |
| 200-Day Average | $11.16 |
| 52-Week Range | $8.48 to $16.93 |
| RSI (14 Days) | 35.8 |
| Average Volume (20 Days) | 13.20K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.97x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 0.97x |
|---|---|
| Quick Ratio | 0.97x |
| Debt / Equity | 0.00x |
| Interest Coverage | 33.69x |
Returns and Efficiency
| Return on Assets (ROA) | -133.75% |
|---|---|
| ROIC (5Y Average) | 70.38% |
| Asset Turnover | 0.02x |
Scores
INKT has an Altman Z-Score of -31.44, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -31.44 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $200.00K over the last 12 months.
| Revenue | $200.00K |
|---|---|
| Revenue Growth (YoY) | -99.99% |
| Gross Profit | $161.44K |
| Operating Income | -$11.44M |
| Pretax Income | -$11.02M |
| Net Income | -$11.02M |
| Reported EPS (TTM) | -$2.25 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $7.47M |
|---|---|
| Total Debt | $0 |
| Net Cash | $7.47M |
| Net Cash Per Share | $1.46 |
| Working Capital | -$271.34K |
| Shareholder Equity | -$16.25M |
| Total Assets | $8.24M |
| Total Liabilities | $24.49M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$7.16M |
|---|---|
| FCF Per Share | -$1.42 |
| Depreciation and Amortization | $146.76K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -5720.70%.
| Gross Margin | 80.72% |
|---|---|
| Operating Margin | -5720.70% |
| Pretax Margin | -5512.48% |
| Net Margin | -5512.48% |
Dividends and Yields
INKT does not pay a dividend.
| Buyback Yield | -11.14% |
|---|---|
| Shareholder Yield | -11.14% |
Stock Splits
The last split was a 1-for-10 reverse split on Jan 28, 2025.
| Last Split Date | Jan 28, 2025 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Peer Position
Against 3 similar companies, INKT has the 2nd highest P/S.
P/S RatioPeer median 83.5x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -100.00%
| P/S Ratio | 236.9x vs 83.5x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -99.99% vs -100.00% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About INKT
What is INKT's market cap?
Mink Therapeutics has a market cap of $47.95M. Its enterprise value, which adds debt and subtracts cash, is $40.48M.
How many shares of INKT are outstanding?
Mink Therapeutics has 5.10M shares outstanding. The count is up 14.84% from a year earlier.
Does INKT pay a dividend?
No. Mink Therapeutics does not pay a dividend.
How much debt does INKT have?
Mink Therapeutics has $0 of total debt and $7.47M of cash and equivalents, a net cash position of $7.47M.
INKT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors